High Rate of HIV Re-suppression After Viral Failure on First Line Antiretroviral Therapy in the Absence of Switch to Second Line. by Gupta, RK et al.
B R I E F R E P O R T H I V / A I D S
High Rate of HIV Resuppression
After Viral Failure on First-line
Antiretroviral Therapy in the
Absence of Switch to Second-line
Therapy
Ravindra K. Gupta,1,a Ruth L. Goodall,2,a Michael Ranopa,2 Cissy Kityo,3
Paula Munderi,4 Fred Lyagoba,4 Lincoln Mugarura,3 Charles F. Gilks,5
Pontiano Kaleebu,4 and Deenan Pillay;1,6 for the DART Virology Group and
Trial Teamb
1Department of Infection, 2Medical Research Council (MRC) Clinical Trials Unit,
University College London, United Kingdom; 3Joint Clinical Research Centre,
Kampala, 4MRC/Uganda Virus Research Institute, Uganda Research Unit on AIDS,
Entebbe, Uganda, 5School of Population Health, University of Queensland, Brisbane,
Australia; and 6Wellcome Trust Africa Centre for Health and Population Sciences,
University of KwaZulu Natal, Mtubatuba, South Africa
In a randomized comparison of nevirapine or abacavir with
zidovudine plus lamivudine, routine viral load monitoring
was not performed, yet 27% of individuals with viral failure
at week 48 experienced resuppression by week 96 without
switching. This supports World Health Organization recom-
mendations that suspected viral failure should trigger adher-
ence counseling and repeat measurement before a treatment
switch is considered.
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Combination antiretroviral therapy (cART) has led to declining
morbidity and mortality in resource-poor settings [1, 2], and
scale-up at the end of 2012 had reached 9.7 million human immu-
nodeﬁciency virus (HIV)–infected individuals worldwide [3]. Op-
timal utilization of ﬁrst-line cART and switch to second-line
therapy in resource-poor settings is a priority. World Health
Organization (WHO) guidelines recommend routine viral load
monitoring (VLM), and switch to second-line therapy is recom-
mended after 2 viral load measurements >1000 copies/mL follow-
ing adherence counseling [4]. However, the WHO document
recognizes that the evidence base for VLM itself is weak. Given
that such a monitoring strategy is likely to be a huge burden for
most resource-limited settings, it is important to increase the evi-
dence base. Furthermore, there is a limited body of data on how
viremia evolves on therapy in absence of VLM, and the impact
on emergence of drug resistance; such information is needed to in-
form treatment guidelines.
The Development of Anti Retroviral Therapy in Africa
(DART) study compared clinical monitoring only with clinical
and laboratory monitoring (CD4 and routine blood tests in-
cluding biochemistry and full blood count), with switch to
second-line therapy on clinical and immunologic criteria.
This study demonstrated good clinical outcomes in both arms
over the 5-year follow-up period [5]. In a substudy of DART,
a comparison of zidovudine (ZDV)/lamivudine (3TC)/nevira-
pine (NVP) vs ZDV/3TC/abacavir (ABC) (NORA Study)
showed triple nucleosides (ZDV/3TC/ABC) to be associated
with higher rates of virologic and immunologic failure than the
nonnucleoside reverse transcriptase inhibitor (NNRTI)–based
regimen (ZDV/3TC/NVP) at 48 weeks [6, 7]. Here we report
virologic outcomes at 96 weeks, demonstrating substantial resup-
pression following earlier viremia despite not switching.
METHODS
The NORA Study enrolled 600 previously untreated and
asymptomatic Ugandan participants with CD4 counts of
<200 cells/µL, randomly assigned to coformulated ZDV/ 3TC
and either ABC and NVP placebo (ABC arm), or ABC placebo
and NVP (NVP arm). Each drug was taken twice daily. After 24
weeks, participants continued to receive the study drugs open
label and were followed as part of DART for a minimum of 4
years. In a separate randomized substudy, participants with a
CD4 count ≥300 cells/µL at 48 or 72 weeks after ART initiation
were eligible to be randomized to continuous therapy or struc-
tured treatment interruption (STI) with repeated 12-week peri-
ods on or off therapy [8]. Viral loads were retrospectively
measured using Roche Amplicor 1.5.
Analyses were based on participants who were alive, in fol-
low-up, and still on ﬁrst-line therapy at week 96, and who
were not randomized to the STI arm in the STI substudy.
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Although the latter exclusion was essential because of the effect
of STIs on viral load (and also possibly development of drug re-
sistance), it introduces a different bias as eligibility for the STI
substudy was related to earlier viral load values via the CD4
count inclusion criterion. The effect of this is the selective exclu-
sion of participants with a good early virologic response and
therefore, in crude analyses, underestimation of the rate of viral
suppressionatweek96.To account for this bias, inverse probability
weights (separate for the 2 NORA arms) were used to up-weight
participants who were randomized to continuous therapy.
Week 96 samples with a viral load >1000 copies/mL under-
went resistance testing by standard population sequencing of
pol [6]. The frequencies of resistance-associated mutations [9]
were calculated both for all participants (intention-to-treat)
and for participants who had made no major substitutions
(deﬁned in the Results section) to their initial regimen (on-
treatment). Participants with baseline resistance were excluded
from analyses of resistance.
Ethics approval both for DART and the NORA substudy was
obtained both in Uganda (Uganda Research Unit on AIDS Sci-
ence and Ethics Committee) and the United Kingdom (Imperial
College).
RESULTS
Of the 600 participants randomized in NORA (300 ABC arm,
300 NVP arm), 32 died before week 96 (13 ABC, 19 NVP), 21
were lost to follow-up (10 ABC, 11 NVP), and 107 were random-
ized to structured treatment interruption (37 ABC, 70 NVP).
Seven participants (4 ABC, 3 NVP) switched to a second-line
regimen based on lopinavir/ritonavir after week 48 and are ex-
cluded from all analyses; all achieved virologic suppression by
96 weeks. The number left for evaluation at week 96 was 236
and 197 in the ABC and NVP arms, respectively (Supplementary
Figure 1). Twenty-ﬁve (11%) participants made a substitution in
the ABC arm (from ABC to NVP or tenofovir [TDF]) and 28
(14%) in the NVP arm (from NVP to ABC or TDF).
Consistent with previously reported week 48 data [6], the dis-
tribution of viral load at week 96 differed between the 2 arms
(P < .001; Table 1), with a greater proportion of participants in
the NVP arm achieving viral load suppression <1000 copies/
mL. The viral load in the majority of participants with suppres-
sion was <200 copies/mL in both arms (91% and 95% of those
<1000 copies/mL in the ABC and NVP arms, respectively).
Table 1 shows the association between viral load at week 48 and
week 96 for individual participants. Participants with viral
load <1000 copies/mL at week 48 were likely to remain <1000
copies/mL at 96 weeks, although more so in the NVP arm (96%
[149/156]) than in the ABC arm (82% [148/180]) (P = .003).
Nineteen of 70 (27%) of individuals (12/46 ABC vs 7/24 NVP;
P = .82) with viral load >1000 copies/mL at week 48 experienced Ta
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resuppression by week 96, indicating issues with adherence.
Sixty-seven of these 70 patients had drug resistance data at
week 48; 10 of 57 (18%) individuals with at least 1 major muta-
tion at week 48 had experienced resuppression by 96 weeks. Re-
sistance patterns present in these 10 individuals were M184V
(n = 3), M184V + D67N, M184V + T215Y, M184V + Y181C,
M184V +D67N + K70R (n = 3), and Y188C. Among the remain-
ing 10 individuals who had no resistance mutations at week 48, 7
(70%) were resuppressed, suggesting an improvement in adher-
ence after week 48. Two of 3 individuals with no resistance re-
sult available at week 48 experienced resuppression by week 96.
Of 91 participants with viral load ≥1000 copies/mL) at week
96, 87 (96%) had a genotype available. Five (4 ABC, 1 NVP)
participants with baseline resistance were excluded, leaving 82
(59 ABC, 23 NVP) patients for analysis. The frequencies of mu-
tations for both the intention-to-treat and on-treatment popu-
lations are given in Supplementary Table 2. The following
description focuses on the on-treatment population for simplic-
ity. A high proportion of failures in the NVP arm had major
NNRTI resistance at week 96 (95%). Thirteen (68%) had only
1 NNRTI mutation, and 5 (26%) participants had 2 NNRTI
mutations. The M184V mutation, conferring resistance to
3TC, was highly prevalent (90% ABC, 89% NVP). The propor-
tion of participants with ≥3 thymidine analogue mutations
(TAMs) at week 96 was similar between the ABC group
(49%) and the NVP group (42%) (P = .79). In the former
group, ABC-speciﬁc mutations L74V and K65R were each
seen in 1 individual. The pan–nucleoside resistance mutation
Q151M was not observed in any individual.
DISCUSSION
We present 2-year virologic data from the DART-NORA study,
highlighting the very good suppression rates achieved using
ZDV/3TC and NVP. Viral failure as deﬁned by WHO [4]was al-
most 3-fold higher with triple nucleoside reverse transcriptase in-
hibitors (NRTIs) containing ZDV/3TC/ABC compared to that
seen in ZDV/3TC/NVP–treated individuals, and supports the
recommendation that this combination not be used for ﬁrst-
line therapy in adults when alternative drugs are available.
There was a high prevalence of extensive NRTI cross-resistance
following viral failure at week 96, with almost half of patients in
each treatment arm having ≥3 TAMs, consistent with other stud-
ies in resource-limited settings [10, 11].Nonetheless, in vivo resid-
ual activity of approximately 1 log in viral load was observed in
both NORA treatment groups overall [12]. The residual activity
in the NVP group was lower than the triple NRTI group, consis-
tent with NNRTI mutations conferring high-level resistance [13].
We noted that most individuals treated with NVP who devel-
oped NNRTI resistance had a single mutation only, consis-
tent with previous reports examining viral failure with both
efavirenz- and NVP-containing regimens [14–17]. This ques-
tions the assumption that prolonged viral failure necessarily
leads to accumulation of NNRTI mutations.
Most importantly, we found that one-quarter of individuals
with viral failure (>1000 copies/mL) at week 48 experienced re-
suppression at 96 weeks even though real-time viral load testing
was not undertaken. This was most likely due to an improve-
ment in adherence. It is notable that resuppression occurred in
the presence of major resistance mutation(s) at week 48 and no
change in therapy, suggesting that strong antiviral activity is pos-
sible despite reduced viral susceptibility, although the role of ad-
herence cannot be ignored. Drug substitutions due to poor
tolerability/side effects did not account for the observed changes
in viral load. In South Africa, where real-time viral monitoring
has taken place, substantial rates of resuppression without mod-
iﬁcation of ART have also been reported, even in patients with
NNRTI resistance [18]. Where VLM is introduced more widely,
our data support WHO recommendations that suspected viral
failure should be addressed by adherence counseling as well as
repeat measurement before consideration of treatment switch.
Such counseling might identify speciﬁc issues with the regimen
and culminate in a treatment substitution to achieve a better ﬁt
for the patient and therefore better adherence.
Supplementary Data
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